— Know what they know.
Not Investment Advice

AURX OTC

Nuo Therapeutics, Inc.
1W: -2.3% 1M: +9.7% 3M: +23.8% YTD: -37.5% 1Y: -35.9% 3Y: +4.2% 5Y: +177.8%
$1.25
+0.00 (+0.00%)
 
OTC · Healthcare · Biotechnology · Tech Score Neutral · Power 51 · $60.5M mcap · 20M float · 0.015% daily turnover · Short 64% of daily vol

Balance Sheet Trends

Total Assets
$2M +55.2% ▲
5Y CAGR: +64.5%
Total Liabilities
$3M +314.7% ▲
5Y CAGR: +33.2%
Shareholders Equity
-$957K -286.2% ▼
Cash & Investments
$549K +93.5% ▲
5Y CAGR: +29.4%
Total Debt
$97K -40.7% ▼
Net Debt
-$452K -277.9% ▼

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2021FY2022FY2023FY2024FY2025
— Assets —
Cash$148K$2M$929K$284K$549K
Short-Term Investments$0$0$0$0$0
Cash & ST Investments$148K$2M$929K$284K$549K
Net Receivables$0$92K$251K$248K$562K
Inventory$0$240K$210K$150K$214K
Other Current Assets$0$251K$174K$159K$56K
Total Current Assets$150K$3M$2M$842K$1M
Property, Plant & Equip.$0$412K$314K$348K$466K
Goodwill & Intangibles$0$0$0$0$0
Long-Term Investments$0$0$0$0$0
Other Non-Current Assets$0$0$0$0$0
Total Non-Current Assets$0$412K$314K$348K$466K
Total Assets$150K$3M$2M$1M$2M
— Liabilities —
Accounts Payable$527K$398K$395K$219K$436K
Short-Term Debt$0$79K$0$0$76K
Deferred Revenue$0$0$0$0$300K
Other Current Liabilities$0$44K$169K$0$930K
Total Current Liabilities$672K$600K$675K$578K$1M
Long-Term Debt$0$0$0$0$21K
Other Non-Current Liab.$0$0$0$0$1M
Total Non-Current Liabilities$0$256K$164K$97K$1M
Total Liabilities$672K$856K$839K$676K$3M
— Equity —
Common Stock$3K$4K$4K$5K$5K
Retained Earnings-$24M-$27M-$30M-$32M-$35M
Accumulated OCI$0$0$0$0$0
Total Stockholders Equity-$523K$2M$1M$514K-$957K
Total Liabilities & Equity$150K$3M$2M$1M$2M
— Key Metrics —
Total Debt$0$335K$256K$164K$97K
Net Debt-$148K-$2M-$673K-$120K-$452K
Total Investments$0$0$0$0$0

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms